Yuanbiao Qiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuanbiao Qiao has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Qingshan Li
School of Pharmacy, Medicinal Basic Research Innovation Center of Chronic Kidney Disease, Ministry of Education, Shanxi Provincial Key Laboratory of Drug Synthesis and Novel Pharmaceutical Preparation Technology Shanxi Medical University Taiyuan China
5 shared publications Chenchen Zhu
Department of Bioscience, Luliang University, Shanxi 033001, PR China
2 shared publicationsLi Song
Department of Bioscience, Luliang University, Shanxi 033001, PR China
2 shared publicationsQian Wang
Department of Bioscience, Luliang University, Shanxi 033001, PR China
2 shared publicationsTianyan Guo
Department of Bioscience, Luliang University, Shanxi 033001, PR China
2 shared publicationsYanhua Yan
Department of Bioscience, Luliang University, Shanxi 033001, PR China
2 shared publications
Latest Publications
- 1 September 2020
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 59 (6) , 515-527
Antifungal resistance-modifying multiplexing action of Momordica charantia protein and phosphorylated derivatives on the basis of growth-dependent gene coregulation in Candida albicans
Fungal growth-dependent gene coregulation is strongly implicated in alteration of gene-encoding target proteases ruling with an antifungal resistance niche and biology of resistant mutants. On the basis of multi-alterative processes in this platform, the resistance-modifying strategy is designed in ketoconazole resistant Candida albicans and evaluated with less selective Momordica charantia protein and allosterically phosphorylated derivatives at the Thr102, Thr24 and Thr255 sites, respectively. We demonstrate absolutely chemo-sensitizing efficacy regarding stepwise-modifying resistance in sensitivity, by a load of only 26.23–40.00 μg/l agents in Sabouraud's dextrose broth. Five successive modifying-steps realize the decreasing of ketoconazole E-test MIC50 from 11.10 to a lower level than 0.10 mg/l. With the ketoconazole resistance-modifying, colony undergoes a high-frequency morphological switch between high ploidy (opaque) and small budding haploid (white). A cellular event in the first modifying-step associates with relatively slow exponential growth (ie, a 4-h delay)-dependent action, mediated by agents adsorption. Moreover, multiple molecular roles are coupled with intracellularly and extracellularly binding to ATP-dependent RNA helicase dbp6; the 0.08–2.45 fold upregulation of TATA-box-binding protein, rRNA-processing protein and translation initiation factor 5A; and the 7.52–55.33% decrease of cytochrome P450 lanosterol 14α-demethylase, glucan 1, 3-β glucosidase, candidapepsin-1 and 1-acylglycerol-3-phosphate O-acyltransferase. Spatial and temporal gene coregulation, in the transcription and translation initiation stages with rRNA-processing, is a new coprocessing platform enabling target protease attenuations for resistance-impairing. An updated resistance-modifying measure of these agents in the low-dose antifungal strategic design may provide opportunities to a virtually safe therapy that is in high dose-dependency. A new platform to modify resistance is fungal growth-dependent gene coregulation. MAP30 and phosphorylated derivatives are candidate resistance-modifying agents. Low-dose stepwise treatment absolutely modifies azole resistance in model fungus.
- 1 September 2020
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 59 (6) , 515-527
Antifungal resistance-modifying multiplexing action of Momordica charantia protein and phosphorylated derivatives on the basis of growth-dependent gene coregulation in Candida albicans
Fungal growth-dependent gene coregulation is strongly implicated in alteration of gene-encoding target proteases ruling with an antifungal resistance niche and biology of resistant mutants. On the basis of multi-alterative processes in this platform, the resistance-modifying strategy is designed in ketoconazole resistant Candida albicans and evaluated with less selective Momordica charantia protein and allosterically phosphorylated derivatives at the Thr102, Thr24 and Thr255 sites, respectively. We demonstrate absolutely chemo-sensitizing efficacy regarding stepwise-modifying resistance in sensitivity, by a load of only 26.23–40.00 μg/l agents in Sabouraud's dextrose broth. Five successive modifying-steps realize the decreasing of ketoconazole E-test MIC50 from 11.10 to a lower level than 0.10 mg/l. With the ketoconazole resistance-modifying, colony undergoes a high-frequency morphological switch between high ploidy (opaque) and small budding haploid (white). A cellular event in the first modifying-step associates with relatively slow exponential growth (ie, a 4-h delay)-dependent action, mediated by agents adsorption. Moreover, multiple molecular roles are coupled with intracellularly and extracellularly binding to ATP-dependent RNA helicase dbp6; the 0.08–2.45 fold upregulation of TATA-box-binding protein, rRNA-processing protein and translation initiation factor 5A; and the 7.52–55.33% decrease of cytochrome P450 lanosterol 14α-demethylase, glucan 1, 3-β glucosidase, candidapepsin-1 and 1-acylglycerol-3-phosphate O-acyltransferase. Spatial and temporal gene coregulation, in the transcription and translation initiation stages with rRNA-processing, is a new coprocessing platform enabling target protease attenuations for resistance-impairing. An updated resistance-modifying measure of these agents in the low-dose antifungal strategic design may provide opportunities to a virtually safe therapy that is in high dose-dependency. A new platform to modify resistance is fungal growth-dependent gene coregulation. MAP30 and phosphorylated derivatives are candidate resistance-modifying agents. Low-dose stepwise treatment absolutely modifies azole resistance in model fungus.
- Open Access
- 29 July 2020
- Published by Springer Nature in Research Square
Formononetin Suppresses Interleukin-6 Production in Lipopolysaccharide-Stimulated Macrophages Via Activation of the AMP-Activated Protein Kinase
Background: Interleukin-6 (IL-6), an inflammatory cytokine, plays a majoy role in the pathogenesis of inflammation and serves as a key marker in the diagnosis and treatment of inflammation and related diseases. Formononetin (FMN), an isoflavone ingredient in various Chinese herbal medicines, inhibits the production of IL-6 in some cells. However, its mechanism of action has not been clearly established. In this study, we aimed to identify whether FMN inhibits IL-6 production in Lipopolysaccharide (LPS)-stimulated macrophages via AMPK activation.Methods: In the current study, the anti-IL-6 mechanism of FMN was evaluated using a macrophage model with LPS stimulation. An inverted microscope was utilized to obtain images of cells. Nuclear staining assay and CCK-8 assay were used to identify the viability of ANA-1 cells. The expression of IL-6 in cells was investigated by Enzyme-linked immunosorbent (ELISA) and Western blotting. The expression of AMP-activated protein kinase (AMPK) was determined by Western blotting and phosphorylation of AMPK was determined by Western blotting and Immunofluorescence assay. Bioinformatic analysis was used to predict potential targets of FMN. Results: we found that FMN reduced the expression of IL-6 in ANA-1 cells and increased the phosphorylation of AMPK. The effect of FMN was similar to that of acadesine, an AMPK activator, which also reduced IL-6 expression in LPS-induced ANA-1 cells and increased AMPK phosphorylation. Its combination with dorsomorphin (an AMPK inhibitor), however, reversed the effects of FMN on AMPK phosphorylation and IL-6 expression. The target of FMN was identified as the cAMP-dependent protein kinase inhibitor alpha, as searched in Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and further verified with the STRING database. Conclusions: In conclusion, our findings suggest that FMN effectively inhibits IL-6 production by activating AMPK in LPS-stimulated macrophages.
- 29 July 2020
- Published by Springer Nature in Research Square
Open AccessFormononetin Suppresses Interleukin-6 Production in Lipopolysaccharide-Stimulated Macrophages Via Activation of the AMP-Activated Protein Kinase
Background: Interleukin-6 (IL-6), an inflammatory cytokine, plays a majoy role in the pathogenesis of inflammation and serves as a key marker in the diagnosis and treatment of inflammation and related diseases. Formononetin (FMN), an isoflavone ingredient in various Chinese herbal medicines, inhibits the production of IL-6 in some cells. However, its mechanism of action has not been clearly established. In this study, we aimed to identify whether FMN inhibits IL-6 production in Lipopolysaccharide (LPS)-stimulated macrophages via AMPK activation.Methods: In the current study, the anti-IL-6 mechanism of FMN was evaluated using a macrophage model with LPS stimulation. An inverted microscope was utilized to obtain images of cells. Nuclear staining assay and CCK-8 assay were used to identify the viability of ANA-1 cells. The expression of IL-6 in cells was investigated by Enzyme-linked immunosorbent (ELISA) and Western blotting. The expression of AMP-activated protein kinase (AMPK) was determined by Western blotting and phosphorylation of AMPK was determined by Western blotting and Immunofluorescence assay. Bioinformatic analysis was used to predict potential targets of FMN. Results: we found that FMN reduced the expression of IL-6 in ANA-1 cells and increased the phosphorylation of AMPK. The effect of FMN was similar to that of acadesine, an AMPK activator, which also reduced IL-6 expression in LPS-induced ANA-1 cells and increased AMPK phosphorylation. Its combination with dorsomorphin (an AMPK inhibitor), however, reversed the effects of FMN on AMPK phosphorylation and IL-6 expression. The target of FMN was identified as the cAMP-dependent protein kinase inhibitor alpha, as searched in Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and further verified with the STRING database. Conclusions: In conclusion, our findings suggest that FMN effectively inhibits IL-6 production by activating AMPK in LPS-stimulated macrophages.
- Open Access
- 23 September 2017
- Published by Elsevier in Data in Brief
- Vol. 15, 370-375
Dataset on preparation of the phosphorylated counterparts of a Momordica charantia protein for studying antifungal activities against susceptible dose-dependent C. albicans to antimycotics
- 23 September 2017
- Published by Elsevier in Data in Brief
- Vol. 15, 370-375
Open AccessDataset on preparation of the phosphorylated counterparts of a Momordica charantia protein for studying antifungal activities against susceptible dose-dependent C. albicans to antimycotics
- Open Access
- 5 September 2017
- Published by Walter de Gruyter GmbH in Green Processing and Synthesis
- Vol. 7 (4) , 334-343
Sulfates of Sorghum vinegar residue waste as potential catalysts
A sealed wet curing design on sulfating Sorghum vinegar residue waste is drilled with sulfo/sulfoalkyl chemicals. Sulfation degrees in the case of reactions with sulfuric acid, sodium sulfite, sulfamic acid, benzenesulfonic acid, p -toluenesulfonic acid and sodium laurilsulfate range from 14.7 to 36.9 mg sulfo per gram waste. The C–O–S formation gives rise to accessional noncrystallinity and mesoporosity of morphology, a character for potential alternatives in catalysis. Waste sulfates are employed as candidates in catalyzing the condensation of α-glycolic acid and urea substitutes for yielding imidazolidine-2,4-dione derivatives. Catalytic and specific activities in terms of derivative productions are 2.6–34.3 (×10 3 U) and 0.8–5.4 U/mg sulfo, together with the maximal yields of 49.4%–97.6%. Chemical linkage of sulfo/sulfoalkyl groups manifests synergism with intrinsic acidity of waste with respect to catalysis. A rational design of green chemistry is guaranteed by no excess of chemicals and easy recyclability of catalysts.
- 5 September 2017
- Published by Walter de Gruyter GmbH in Green Processing and Synthesis
- Vol. 7 (4) , 334-343
Open AccessSulfates of Sorghum vinegar residue waste as potential catalysts
A sealed wet curing design on sulfating Sorghum vinegar residue waste is drilled with sulfo/sulfoalkyl chemicals. Sulfation degrees in the case of reactions with sulfuric acid, sodium sulfite, sulfamic acid, benzenesulfonic acid, p -toluenesulfonic acid and sodium laurilsulfate range from 14.7 to 36.9 mg sulfo per gram waste. The C–O–S formation gives rise to accessional noncrystallinity and mesoporosity of morphology, a character for potential alternatives in catalysis. Waste sulfates are employed as candidates in catalyzing the condensation of α-glycolic acid and urea substitutes for yielding imidazolidine-2,4-dione derivatives. Catalytic and specific activities in terms of derivative productions are 2.6–34.3 (×10 3 U) and 0.8–5.4 U/mg sulfo, together with the maximal yields of 49.4%–97.6%. Chemical linkage of sulfo/sulfoalkyl groups manifests synergism with intrinsic acidity of waste with respect to catalysis. A rational design of green chemistry is guaranteed by no excess of chemicals and easy recyclability of catalysts.
- 1 April 2015
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 483 (1-2) , 188-199
Zirconium phosphatidylcholine-based nanocapsules as an in vivo degradable drug delivery system of MAP30, a momordica anti-HIV protein
- 1 April 2015
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 483 (1-2) , 188-199
Zirconium phosphatidylcholine-based nanocapsules as an in vivo degradable drug delivery system of MAP30, a momordica anti-HIV protein